Matinas BioPharma (MTNB) Misses Q3 EPS by 1c; Reports Cash and Cash Equivalents of $53.8M
Matinas BioPharma (NYSE: MTNB) reported Q3 EPS of ($0.03), $0.01 worse than the analyst estimate of ($0.02).
For earnings history and earnings-related data on Matinas BioPharma (MTNB) click here.